TNF and rheumatoid arthritis: The last decade has seen an increasing number of novel treatments targeting a variety of different immunological pathways involved in the RA pathology, including TNFα, IL-1 and IL-6 production and intracellular pathways such Janus kinase (JAK) inhibitors.